GeneCentric completed $8 million Series C Round funding
Sector:
Biotech
Life Science
06/18/2025
Durham, NC USA
GeneCentric
completed $8 million Series C Round funding. Investors include
Hatteras Venture Partners (lead), IAG Capital Partners, Alexandria Venture Investments, Labcorp Venture Fund.
About
GeneCentric Therapeutics, Inc., a leader in gene expression biomarkers and next-generation companion diagnostic development, is based in Durham, North Carolina. The company has developed a deep pipeline of gene signatures and related diagnostic tests by parsing the complexity of tumor biology using their RNA-based Tumor and Immune Micro-Environment (rT(I)ME) Explorer platform and proprietary AI-based technology to identify responder populations to oncology therapeutics. Along with its ExpressCT™ technology, these signatures can be applied to liquid biopsy through its GenomicsNext™ platform. GeneCentric commercializes its technology through strategic collaborations with biopharmaceutical and diagnostics companies in applications throughout preclinical testing, clinical drug development, and commercialization lifecycle phases.
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
